Search

Oct 4, 2024
Oxford, UK based Enara Bio announced a $32.5M series B to further its work developing TCR based therapies that target antigens found in the 'dark genome'
President & CEO Kevin Pojasek describes how the company searches for these novel cancer-specific antigens that are from areas of the...